초록 ▼

A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic i

A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic interactions to generate a complex, wherein the cationic molecules are not comprised in a liposome; and (b) covalently binding the complex to a targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. Use of the particles and compositions comprising same are also disclosed.

대표청구항 ▼

1. A particle for delivery of a polynucleotide to a target cell, generated according to a method comprising: (a) contacting the polynucleotide with a composition comprising 1,2-Dilauroyl-sn-Glicero-3-Phosphoethanolamine (DLPE) and 1,2-Dilauroyl-sn-Glicero-3-Glycerol (DLPG), wherein said DLPE and DLP

1. A particle for delivery of a polynucleotide to a target cell, generated according to a method comprising: (a) contacting the polynucleotide with a composition comprising 1,2-Dilauroyl-sn-Glicero-3-Phosphoethanolamine (DLPE) and 1,2-Dilauroyl-sn-Glicero-3-Glycerol (DLPG), wherein said DLPE and DLPG condense the polynucleotide by electrostatic interactions to generate a complex, and wherein said DLPE and DLPG are not comprised in a liposome; and(b) covalently binding said complex to a glycosaminoglycan targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. 2. The particle of claim 1, being about 100 nm or less in diameter when dried on a silicon surface. 3. The particle of claim 1, being from about 30 nm to about 300 nm in diameter in solution. 4. The particle of claim 1, being spherical in shape, being charged or neutral. 5. The particle of claim 1, wherein lipids in the composition consist of DLPE and DLPG. 6. The particle of claim 1, wherein said glycosaminoglycan comprises HA. 7. The particle of claim 6, further comprising at least one additional targeting moiety, said additional targeting moiety being selected from the group consisting of an antibody, an antibody fragment, a receptor ligand and an aptamer. 8. A composition comprising a plurality of the particles of claim 1 and being substantially homogeneous. 9. The composition of claim 8, wherein said particles comprise a core of siRNA and DLPE and DLPG, and a shell comprising targeting moieties, said targeting moieties comprising hyaluronic acid (HA); and each of the particles of said plurality of particles comprises a zeta potential of about −40 mV and wherein each of the particles of said plurality of particles is from about 100 nm to about 300 nm in diameter when in solution. 10. The composition of claim 8, wherein; said particles comprise a core of miRNA and DLPE and DLPG, and a shell comprising targeting moieties, said targeting moieties comprising hyaluronic acid (HA); andeach of the particles of said plurality of particles is from about 30 nm to about 50 nm in diameter when in solution. 11. A particle for delivery of a polynucleotide to a target cell, comprising a core of a complex between a polynucleotide and 1,2-Dilauroyl-sn-Glicero-3-Phosphoethanolamine (DLPE) and 1,2-Dilauroyl-sn-Glicero-3-Glycerol (DLPG), surrounded by a shell comprising hyaluronic acid (HA) as a targeting moiety covalently bound to the complex, wherein: (i) the complex is not comprised in a liposome;(ii) the particle comprises a zeta potential of about −10 to −75 mV; and(iii) the particle is from about 30 nm to about 300 nm in diameter when in solution. 12. The particle of claim 11, comprising a zeta potential of about −40 mV. 13. The particle of claim 11, comprising more than about 6,000 siRNA or miRNA molecules. 14. A method of generating a particle, said particle being for delivery of a polynucleotide to a target cell, the method comprising: (a) contacting the polynucleotide with a composition comprising 1,2-Dilauroyl-sn-Glicero-3-Phosphoethanolamine (DLPE) and 1,2-Dilauroyl-sn-Glicero-3-Glycerol (DLPG), wherein said DLPE and DLPG condense the polynucleotide by electrostatic interactions to generate a complex, and wherein said DLPE and DLPG are not comprised in a liposome; and(b) covalently binding said complex to a targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. 15. The method of claim 14, wherein the polynucleotide is selected from single stranded and double stranded DNA, RNA, or both. 16. The method of claim 14, wherein said composition comprises a further neutral lipid. 17. The method of claim 16, wherein said neutral lipid comprises dioleoylphosphatidylethanolamine (DOPE). 18. The method of claim 14, wherein said composition comprises further anionic phospholipids. 19. The method of claim 18, wherein said anionic phospholipids are selected from the group consisting of phosphatidylserine, phosphatidic acid, and phosphatidyl glycerol. 20. The method of claim 14, wherein said composition further comprises cholesterol. 21. The method of claim 14, wherein said targeting moiety comprises a polypeptide targeting moiety, selected from the group consisting of an antibody, an antibody fragment, an aptamer and a receptor ligand. 22. The method of claim 14, wherein said targeting moiety comprises a glycosaminoglycan selected from the group consisting of hyaluronic acid (HA), keratan sulfate, chondroitin sulfate, heparin sulfate, heparan sulfate, dermatin sulfate, salts thereof, and mixtures thereof. 23. The method of claim 22, further comprising activating said glycosaminoglycan prior to step (b), wherein said activating is effected by incubating said glycosaminoglycan in an acidic buffer. 24. The method of claim 14, wherein said targeting moiety comprises HA and said polynucleotide agent comprises an siRNA or miRNA. 25. The method of claim 14, wherein said complex is not extruded prior to step (b). 26. The method of claim 14, wherein said composition further comprises a cationic molecule selected from the group consisting of a cationic polypeptide, a cationic lipid, a cationic surfactant and a synthetic polymer. 27. The method of claim 14, wherein said composition further comprises a lipid selected from the group consisting of dioleoyl-1,2-diacyl-3-trimethylammonium-propane (DOTAP, at 18:1; 14:0; 16:0, 18:0) and N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethlylammonium chloride (DOTMA); dimethyldioctadecylammonium (DDAB); 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (Ethyl PC, at 12:0; 14:0; 16:0; 18:0; 18:1; 16:0-18:1); 1,2-di-(9Z-octadecenoyl)-3-dimethylammonium-propane and 3β-(N—(N′,N′-dimethylaminoethane)-carbamoyl)cholesterol hydrochloride (DC-Cholesterol). 28. The method of claim 14, wherein said composition further comprises phosphatidylcholine. 29. The method of claim 14, wherein the polynucleotide comprises an RNA silencing agent selected from the group consisting of an sRNA, a miRNA, an antisense oligonucleotide and a ribozyme. 30. A method of down-regulating a gene of interest in a target cell, the method comprising contacting particles with the target cell, wherein the particles are generated according to the method of claim 29 and said target cell expresses CD44, thereby down-regulating a gene of interest in a target cell. 31. A method of downregulating a gene of interest in a subject, the method comprising administering to cells of the subject the particles of claim 1, wherein the polynucleotide downregulates expression of the gene of interest. 32. The method of claim 31, wherein said administering is effected in vivo or ex-vivo. 33. The method of claim 31, wherein the polynucleotide comprises an RNA silencing agent selected from the group consisting of an sRNA, a miRNA, an antisense oligonucleotide and a ribozyme. 34. The method of claim 33, wherein said RNA silencing agent is selected to down-regulate expression of an oncogene and/or expression of a gene associated with viability of cancer cells. 35. The method of claim 31, wherein the gene is an oncogene. 36. The method of claim 31, wherein the gene is K-ras, c-myc, bcr/abl, c-myb, c-fms, c-fos, a c-erbB, a gene encoding epidermal growth factor or its receptor, a gene encoding fibroblast growth factor-binding protein, a matrix metalloproteinase gene, an adhesion-molecule gene, a tumor suppressor gene, an angiogenesis gene, a metastasis gene, a gene encoding stromelysin, a gene encoding tumor necrosis factor, a human papilloma virus gene, a hepatitis B virus gene, a hepatitis C virus gene, or a cytomegalovirus (CMV) gene.